[go: up one dir, main page]

MX2018005230A - Terapia de combinacion de un inhibidor del ensamble de la capside del hbv y un interferon. - Google Patents

Terapia de combinacion de un inhibidor del ensamble de la capside del hbv y un interferon.

Info

Publication number
MX2018005230A
MX2018005230A MX2018005230A MX2018005230A MX2018005230A MX 2018005230 A MX2018005230 A MX 2018005230A MX 2018005230 A MX2018005230 A MX 2018005230A MX 2018005230 A MX2018005230 A MX 2018005230A MX 2018005230 A MX2018005230 A MX 2018005230A
Authority
MX
Mexico
Prior art keywords
interferon
combination therapy
cavide
hbv
assembly
Prior art date
Application number
MX2018005230A
Other languages
English (en)
Other versions
MX377531B (es
Inventor
Gao Lu
Shen Hong
Wildum Steffen
Yang Guang
Najera Isabel
Shen Fang
Shi Liping
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2018005230A publication Critical patent/MX2018005230A/es
Publication of MX377531B publication Critical patent/MX377531B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención está dirigida a composiciones y métodos para tratar la infección por el virus de la hepatitis B. En particular, la presente invención está dirigida a una terapia de combinación que comprende la administración de un inhibidor del ensamble de cápside del HBV y un interferón para su uso en el tratamiento de infecciones por el virus de la hepatitis B.
MX2018005230A 2015-11-03 2016-10-31 Terapia de combinación de un inhibidor del ensamble de la cápside del hbv y un interferón. MX377531B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2015093688 2015-11-03
PCT/EP2016/076195 WO2017076791A1 (en) 2015-11-03 2016-10-31 Combination therapy of an hbv capsid assembly inhibitor and an interferon

Publications (2)

Publication Number Publication Date
MX2018005230A true MX2018005230A (es) 2018-08-15
MX377531B MX377531B (es) 2025-03-10

Family

ID=57223681

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005230A MX377531B (es) 2015-11-03 2016-10-31 Terapia de combinación de un inhibidor del ensamble de la cápside del hbv y un interferón.

Country Status (12)

Country Link
US (2) US10596173B2 (es)
EP (1) EP3370759A1 (es)
JP (2) JP6668468B2 (es)
KR (1) KR102181168B1 (es)
CN (1) CN108135979A (es)
AU (1) AU2016349685A1 (es)
BR (1) BR112018009009A8 (es)
CA (1) CA2999944A1 (es)
HK (1) HK1255463A1 (es)
IL (1) IL258147A (es)
MX (1) MX377531B (es)
WO (1) WO2017076791A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3114128T (pt) * 2014-03-07 2019-02-27 Hoffmann La Roche Novas heteroarildihidropirimidinas fundidas em 6 para o tratamento e profilaxia da infeção pelo vírus da hepatite b.
CN107427514B (zh) * 2015-03-16 2021-07-13 豪夫迈·罗氏有限公司 使用tlr7激动剂和hbv衣壳装配抑制剂的组合治疗
JP6622392B2 (ja) 2015-10-02 2019-12-18 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｐｄ１とｔｉｍ３に特異的な二重特異性抗体
BR102017010009A2 (pt) 2016-05-27 2017-12-12 Gilead Sciences, Inc. Compounds for the treatment of hepatitis b virus infection
JOP20180008A1 (ar) 2017-02-02 2019-01-30 Gilead Sciences Inc مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
CN117003887A (zh) 2017-04-03 2023-11-07 豪夫迈·罗氏有限公司 抗pd-1抗体与突变体il-2或与il-15的免疫缀合物
US11285207B2 (en) 2017-04-05 2022-03-29 Hoffmann-La Roche Inc. Bispecific antibodies specifically binding to PD1 and LAG3
EP3645516A4 (en) 2017-06-27 2021-07-07 Janssen Pharmaceutica NV HETEROARYLDIHYDROPYRIMIDE DERIVATIVES AND METHODS OF TREATMENT OF HEPATITIS B INFECTIONS
KR20200032702A (ko) 2017-07-27 2020-03-26 지앙수 헨그루이 메디슨 컴퍼니 리미티드 피페라진 헤테로아릴 유도체, 그 제조 방법 및 의약에서 이의 용도
EP3697792A4 (en) * 2017-10-18 2021-10-13 Sunshine Lake Pharma Co., Ltd. DIHYDROPYRIMIDINE COMPOUNDS AND THEIR USES IN MEDICINE
US11447489B2 (en) 2017-12-28 2022-09-20 Hoffmann-La Roche Inc. Dihydropyrimidinylthiazole for the treatment and prophylaxis of hepatitis B virus infection
US11053235B2 (en) 2018-08-09 2021-07-06 Janssen Sciences Ireland Unlimited Company Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases
AU2019373090B2 (en) 2018-10-31 2023-05-25 The University Of Sydney Compositions and methods for treating viral infections
US20220048919A1 (en) 2018-12-20 2022-02-17 Janssen Phrmaceutica NV Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infections
WO2020193459A1 (en) 2019-03-25 2020-10-01 F. Hoffmann-La Roche Ag Solid forms of a compound of hbv core protein allosteric modifier
EP4031140A1 (en) * 2019-09-20 2022-07-27 F. Hoffmann-La Roche AG Method of treating hbv infection using a core protein allosteric modulator
WO2021063852A1 (en) * 2019-09-30 2021-04-08 F. Hoffmann-La Roche Ag Substituted pyrimidine for the treatment and prophylaxis of hepatitis b virus infection
US20230399320A1 (en) * 2020-11-06 2023-12-14 Pelemed Co., Ltd. Novel capsid assembly inhibitor
CN114907355A (zh) * 2021-02-09 2022-08-16 上海维申医药有限公司 一种二氢嘧啶类化合物、其制备方法及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
NZ276943A (en) 1993-11-10 1998-02-26 Schering Corp Substituted For Alpha-interferon conjugated to a non-antigenic polymer (preferably a polyalkylene oxide) and its preparation
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
WO2001045712A1 (de) * 1999-12-22 2001-06-28 Bayer Aktiengesellschaft Arzneimittelkombinationen gegen virale erkrankungen
CN101328169B (zh) 2007-06-18 2011-05-25 张中能 一种乙氧碳酰基-取代噻唑二氢嘧啶
AU2008265397C1 (en) 2007-06-18 2013-08-29 Sunshine Lake Pharma Co., Ltd. Bromo-phenyl substituted thiazolyl dihydropyrimidines
CN101328170B (zh) 2007-06-18 2011-09-14 张中能 一种氟苯基-取代噻唑二氢嘧啶
CN101328168B (zh) 2007-06-18 2011-09-07 张中能 一种乙氧碳酰基-取代噻唑二氢嘧啶
PL2888241T3 (pl) * 2012-08-24 2017-12-29 Sunshine Lake Pharma Co., Ltd. 2,4,5,6-Podstawione pochodne 3,6-dihydropirymidyny jako inhibitory polimerazy wirusa zapalenia wątroby typu B (HBV) do leczenia np. przewlekłego zapalenia wątroby
CN103664925B (zh) 2012-09-07 2018-01-23 广东东阳光药业有限公司 杂芳基取代的二氢嘧啶类化合物及其在药物中的应用
BR112015004113A2 (pt) * 2012-09-10 2017-07-04 Hoffmann La Roche 6-aminoácido heteroarila diidropirimidinas para o tratamento e profilaxia da infecção pelo vírus da hepatite b
US9266904B2 (en) * 2013-05-17 2016-02-23 Hoffmann-La Roche Inc. 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection
MX2016006564A (es) 2013-11-19 2017-09-12 Sunshine Lake Pharma Co Ltd Compuestos dihidropirimidina y su aplicacion en productos farmaceuticos.
US20150216938A1 (en) * 2014-02-05 2015-08-06 Novira Therapeutics Inc. Combination therapy for treatment of hbv infections
PT3114128T (pt) * 2014-03-07 2019-02-27 Hoffmann La Roche Novas heteroarildihidropirimidinas fundidas em 6 para o tratamento e profilaxia da infeção pelo vírus da hepatite b.

Also Published As

Publication number Publication date
KR102181168B1 (ko) 2020-11-23
BR112018009009A8 (pt) 2019-02-26
AU2016349685A1 (en) 2018-03-15
WO2017076791A1 (en) 2017-05-11
US20180250301A1 (en) 2018-09-06
JP2020100636A (ja) 2020-07-02
CN108135979A (zh) 2018-06-08
BR112018009009A2 (pt) 2018-10-30
IL258147A (en) 2018-05-31
KR20180058828A (ko) 2018-06-01
CA2999944A1 (en) 2017-05-11
JP6668468B2 (ja) 2020-03-18
MX377531B (es) 2025-03-10
HK1255463A1 (zh) 2019-08-16
JP2018531272A (ja) 2018-10-25
US20200276198A1 (en) 2020-09-03
US10596173B2 (en) 2020-03-24
EP3370759A1 (en) 2018-09-12

Similar Documents

Publication Publication Date Title
MX2018005230A (es) Terapia de combinacion de un inhibidor del ensamble de la capside del hbv y un interferon.
MX2022011756A (es) Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la capsida del vhb.
MX2021014771A (es) Tratamiento combinado con un agonista de tlr7 y un inhibidor de montaje de capsida de hbv.
JOP20180008A1 (ar) مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
CL2019001433A1 (es) Moduladores de la proteína core de la hepatitis b. (divisional solicitud 201800684)
MX2020011808A (es) Combinaciones y metodos que comprenden un inhibidor del ensamblaje de la capside.
PH12018550150A1 (en) Elimination of hepatitis b virus with antiviral agents
UA117518C2 (uk) 6-конденсовані гетероарилдигідропіримідини для лікування та профілактики зараження вірусом гепатиту b
MX383447B (es) Combinación de un inhibidor de ensamblaje de cápsido y peginterferón alfa-2a y sus usos para tratar infecciones por virus de la hepatitis b (vhb).
EA201791515A1 (ru) Соединения пиразина для лечения инфекционных заболеваний
EA201792069A1 (ru) Производные азокана и азонана и способы лечения инфекций гепатита в
EA201691440A1 (ru) Производные азепана и способы лечения инфекций гепатита в
MX2021010145A (es) Derivados de amida utiles en el tratamiento de una infeccion por vhb o de enfermedades inducidas por vhb.
AR111908A1 (es) Composiciones terapéuticas y métodos de tratamiento de hepatitis b
EP3370723A4 (en) TREATMENT OF HEPATITIS DELTA VIRUS INFECTION
NZ785788A (en) Antibody compositions and methods for treating hepatitis b virus infection
MX2016013434A (es) Inhibidores potentes y selectivos del virus de la hepatitis c.
JOP20190214A1 (ar) ثنائي هيدرو إيندين-?-كربوكساميدات ونظائر منها بها استبدال، وطرق تستخدمها
EA201790776A1 (ru) Комбинированные композиции длительного действия и способы лечения гепатита с
EA201790771A1 (ru) Фармацевтические композиции длительного действия для лечения гепатита c
PH12018502320A1 (en) Reagents for treatment of hepatitis b virus (hbv) infection and use thereof
MX2022007909A (es) Combinacion farmaceutica de agentes antivirales que actuan sobre hbv y/o un inmunomodulador para el tratamiento de hbv.
TR201910305T4 (tr) Viral enfeksiyonları tedavi etmek için bileşikler.
PL3710025T3 (pl) Biomasa sinic do zastosowania w leczeniu zakażenia wirusem zapalenia wątroby typu b
EA201892348A1 (ru) Комбинации и способы, включающие ингибитор сборки капсида

Legal Events

Date Code Title Description
FG Grant or registration